Sitagliptin phosphate: A DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
References (48)
- et al.
The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Lancet
(2006) - et al.
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
Clin Ther
(2006) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Regul Pept
(1999)- et al.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Clin Ther
(2006) Diabetes [WHO Web site]
The Dangerous Toll of Diabetes
- et al.
Economic costs of diabetes in the US in 2002
Diabetes Care
(2003) - et al.
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement for the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care
(2006) Januvia (sitagliptin) [package insert]
(2006)DPP-4 inhibitors and their potential role in the management of type 2 diabetes
Int J Clin Pract
(2006)
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
J Clin Endocrinol Metab
(2001)
Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV
Crit Rev Clin Lab Sci
(2003)
(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
J Med Chem
(2005)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: Potential importance of selectivity over dipeptidyl peptidases 8 and 9
Diabetes
(2005)
Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs
Drug Metab Dispos
(2007)
Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans
Drug Metab Dispos
(2007)
Pharmaco-kinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Clin Pharmacol Ther
(2005)
Multiple dose administration of sitagliptin, a dipeptidyl peptide IV (DPP-4) inhibitor, in healthy Japanese subjects
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
J Clin Endocrinol Metab
(2006)
Characterization of two cyclic metabolites of sitagliptin
Drug Metab Dispos
(2007)
Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein
J Pharmacol Exp Ther
(2007)
Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor
Diabetes Care
(2007)
Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV (DPP-IV) inhibitor
Clin Pharmacol Ther.
(2006)
Lack of a clinically meaningful effect on age, gender or obesity on the pharmacokinetics of the DPP-IV inhibitor MK-0431
Cited by (0)
Copyright © 2007 Published by Elsevier Inc.